Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: Cohort study

BMJ (Online)

Volumn 358, Issue , 2017, Pages

  Huybrechts, Krista F ^a   Bateman, Brian T ^a   Desai, Rishi J ^a   Hernandez Diaz, Sonia ^b   Rough, Kathryn ^a,b   Mogun, Helen ^a   Kerzner, Leslie S ^c   Davis, Jonathan M ^d   Stover, Megan ^e   Bartels, Devan ^c   Cottral, Jennifer ^c   Patorno, Elisabetta ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUTORPHANOL; CODEINE; DEXTROPROPOXYPHENE; FENTANYL; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; HYPNOTIC AGENT; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; OXYMORPHONE; PENTAZOCINE; PETHIDINE; PSYCHOTROPIC AGENT; TAPENTADOL; TRAMADOL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; NEONATAL ABSTINENCE SYNDROME; NEWBORN; OBSERVATIONAL STUDY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; UNITED STATES; ADVERSE EFFECTS; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; MALE; MEDICAID; MIDDLE AGED; MOOD DISORDERS; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE; PRESCRIPTION; PREVENTION AND CONTROL; PROSPECTIVE STUDY; PSYCHOLOGY; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; ANALGESICS, OPIOID; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MEDICAID; MIDDLE AGED; MOOD DISORDERS; NEONATAL ABSTINENCE SYNDROME; OPIOID-RELATED DISORDERS; PRACTICE PATTERNS, PHYSICIANS'; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANT WOMEN; PRENATAL EXPOSURE DELAYED EFFECTS; PRESCRIPTIONS; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 85026818334     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j3326     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011;60:1487-92.
2. Volkow ND. America's addiction to opioids: heroin and prescription drug abuse. Senate Caucus on International Narcotics Control. https://www. drugabuse. gov/about-nida/legislative-activities/testimony-to-congress/2016/americas-addiction-to-opioids-heroin-prescription-drug-abuse. 2014.
3. Bateman BT, Hernandez-Diaz S, Rathmell JP. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology 2014;120:1216-24. doi:10. 1097/ALN. 0000000000000172
4. Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol 2014;123:997-1002. doi:10. 1097/AOG. 0000000000000208
5. van Amsterdam J, van den Brink W. The misuse of prescription opioids: a threat for Europe?Curr Drug Abuse Rev 2015;8:3-14. doi:10. 2174/187447370801150611184218
6. Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106, 000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008;65:653-60. doi:10. 1111/j. 1365-2125. 2008. 03102. x
7. Hudak ML, Tan RCCommittee On DrugsCommittee On Fetus And NewbornAmerican Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics 2012;129:e540-60. doi:10. 1542/peds. 2011-3212
8. Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015;35:650-5. doi:10. 1038/jp. 2015. 36
9. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012;307:1934-40. doi:10. 1001/jama. 2012. 3951
10. FDA Drug Safety Communication. Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. http://www. fda. gov/Drugs/DrugSafety/ucm243903. htm. 2011.
11. Carrasco M, Rao SC, Bearer CF, Sundararajan S. Neonatal gabapentin withdrawal syndrome. Pediatr Neurol 2015;53:445-7. doi:10. 1016/j. pediatrneurol. 2015. 06. 023
12. Hanley GE, Mintzes B. Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. BMC Pregnancy Childbirth 2014;14:242. doi:10. 1186/1471-2393-14-242
13. Hwang CS, Kang EM, Kornegay CJ, Staffa JA, Jones CM, McAninch JK. Trends in the concomitant prescribing of opioids and benzodiazepines, 2002-2014. Am J Prev Med 2016;51:151-60. doi:10. 1016/j. amepre. 2016. 02. 014
14. Desai RJ, Huybrechts KF, Hernandez-Diaz S. Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. BMJ 2015;350:h2102. doi:10. 1136/bmj. h2102
15. Palmsten K, Huybrechts KF, Mogun H. Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations. PLoS One 2013;8:e67405.. doi:10. 1371/journal. pone. 0067405
16. Von Korff M, Saunders K, Thomas Ray G. De facto long-term opioid therapy for noncancer pain. Clin J Pain 2008;24:521-7. doi:10. 1097/AJP. 0b013e318169d03b
17. Mercadante S, Porzio G, Aielli F. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin 2013;29:661-6. doi:10. 1185/03007995. 2013. 791617
18. Mercadante S, Villari P, Ferrera P. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage 2006;32:175-9. doi:10. 1016/j. jpainsymman. 2006. 01. 013
19. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, 2016. http://www. clinicalpharmacology. com.
20. Bateman BT, Mhyre JM, Hernandez-Diaz S. Development of a comorbidity index for use in obstetric patients. Obstet Gynecol 2013;122:957-65. doi:10. 1097/AOG. 0b013e3182a603bb
21. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64. doi:10. 1093/aje/154. 9. 854
22. Desai RJ, Rothman KJ, Bateman BT, Hernandez-Diaz S, Huybrechts KF. A Propensity score based fine stratification approach for confounding adjustment when exposure is infrequent. Epidemiology 2017;28:249-57. doi:10. 1097/EDE. 0000000000000595
23. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512-22. doi:10. 1097/EDE. 0b013e3181a663cc
24. Finnegan LP, Connaughton JFJ Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2:141-58.
25. Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG 2009;116:665-71. doi:10. 1111/j. 1471-0528. 2008. 02073. x
26. Jansson LM, Di Pietro JA, Elko A, Williams EL, Milio L, Velez M. Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes. Drug Alcohol Depend 2012;122:213-9. doi:10. 1016/j. drugalcdep. 2011. 10. 003
27. Wachman EM, Newby PK, Vreeland J. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med 2011;5:293-9. doi:10. 1097/ADM. 0b013e3182266a3a
28. Rothman K, Greenland S, Lash T. Validity in Epidemiologic Studies. In: Rothman K, Greenland S, Lash T, eds. Modern Epidemiology. Lippincott Williams & Wilkins, 2012: 128-47.
29. Raffaeli G, Cavallaro G, Allegaert K. Neonatal abstinence syndrome: update on diagnostic and therapeutic strategies. Pharmacotherapy 2017. doi:10. 1002/phar. 1954.
30. Norton JW. Gabapentin withdrawal syndrome. Clin Neuropharmacol 2001;24:245-6. doi:10. 1097/00002826-200107000-00011
31. Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. Ann Pharmacother 2016;50:229-33. doi:10. 1177/1060028015620800
32. Loudin S, Murray S, Prunty L, Davies T, Evans J, Werthammer J. An atypical withdrawal syndrome in neonates prenatally exposed to gabapentin and opioids. J Pediatr 2017;181:286-8. doi:10. 1016/j. jpeds. 2016. 11. 004